Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
187
-
Total 13F shares, excl. options
-
75.8M
-
Shares change
-
+695K
-
Total reported value, excl. options
-
$1.21B
-
Value change
-
+$10.3M
-
Put/Call ratio
-
0
-
Number of buys
-
79
-
Number of sells
-
-89
-
Price
-
$15.96
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q4 2021
216 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q4 2021.
Coherus Oncology, Inc. - Common Stock (CHRS) has 187 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.8M shares
of 115M outstanding shares and own 65.66% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.9M shares), Temasek Holdings (Private) Ltd (7.38M shares), JPMORGAN CHASE & CO (6.69M shares), ALLIANCEBERNSTEIN L.P. (5.71M shares), PERCEPTIVE ADVISORS LLC (5.41M shares), VANGUARD GROUP INC (4.55M shares), STATE STREET CORP (3.82M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), Aristotle Capital Boston, LLC (2.09M shares), and AMERIPRISE FINANCIAL INC (1.69M shares).
This table shows the top 187 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.